Dr. M. Lang

Biography

  Dr. Marc Lang, Ph.D., serves as the Head of Medicinal Chemistry and Executive Director at PIQUR Therapeutics AG. He serves as scientific advisor to several pharmaceutical companies. Dr. Lang has more than 30 years of experience in medicinal chemistry from various fields of research related to antibiotics, antivirals and oncology. Until 2013, hee served as Executive Director of the Medicinal Chemistry Unit for Oncology in Basel and a member of the Global Oncology Decision Board at Novartis Institute for Biomedical Research. Dr. Lang served as the Head of Medicinal Chemistry for Oncology Research Programs at Novartis Pharma AG. In his career, he contributed personally to three compounds on the market: Femara®(aromatase inhibitor); Reyataz® (HIV-protease inhibitor); Tasigna® (Bcr/Abl kinase inhibitor); and several promising compounds in clinical trials. Dr. Lang serves as a Scientific Advisory Board Member of Cellestia Biotech AG and Blueprint Medicines Corporation. He has been a Member of Scientific Advisory Board at SignalChem Lifesciences Corporation since April 2, 2014. Dr. Lang holds a Ph.D. in Chemistry from the University of Strasbourg and was a postdoctoral fellow at the Woodward Research Institute in Basel, Switzerland.

Research Interest

Medicinal Chemistry